Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm pralatrexate study in advanced or metastatic relapsed bladder transitional cell carcinoma
2007-004671-19Phase 2Active
- Sponsor
- Allos Therapeutics
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pralatrexate in transitional cell carcinoma of the bladder (TCC), sponsored by Allos Therapeutics. Primary endpoint: Objective response. Started Mar 2008; status: active.
02
Drugs
pralatrexate
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2007-004671-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004671-19.